Read about our COVID-19 Response. Webinars and Podcasts Newsroom Webinars and Podcasts Insights: Blog Webinars Sepsis Webinar Series: Are you aware of the continuing risk of septic transfusion reactions? We will bring you up to date with the latest, most relevant insights in a series of short educational webinars hosted by experts to cover key subjects: Part 1: Bacterial contamination rates in platelet components Video 1: (Runtime 9 min) Introduction Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus Europe Video 2: (Runtime 20 min) Bacterial contamination rate of platelet components by primary culture and residual risk associated with false negatives: results from two recent meta-analyses Ryan A. Metcalf | Medical Director, Blood Bank Assistant Professor; Inpatient Chief Value Officer; Department of Pathology | University of Utah and ARUP Laboratories Video 3: (Runtime 25 min) Transfusion transmitted bacterial infections in patients: why are they often undetected and underreported? Richard Benjamin | Chief Medical Officer | Cerus Global Headquarters Part 2: Rationale on why bacterial contaminations don’t always cause clinical sepsis Video 1: (Runtime 10 min) Introduction: Review of bacterial risk control strategies for platelet concentrates Marion Lanteri | Global Scientific Affairs Director | Cerus Global Headquarters Video 2: (Runtime 20 min) Merits and pitfalls of automated bacterial culture methods in improving bacterial safety of platelet concentrates Sandra Ramirez-Arcos | Senior Scientist, Canadian Blood Services and Adjunct Professor, University of Ottawa | Ottawa, Canada Video 3: (Runtime 26 min) Reduction in the risk of bacterial contamination, platelet components prepared with Amotosalen-UVA photochemical treatment. What can we conclude after 15 years of routine experience? Laurence Corash | Chief Scientific Officer | Cerus Global Headquarters Podcasts Preparing Our Blood Supply for the Next Pandemic with Dr. Susan Stramer August 2020 Dr. Stramer discusses how pathogen outbreaks can impact blood safety and availability, and what to do about it. How can blood suppliers prepare for the next pandemic? While SARS-Cov-2 does not appear to be transfusion-transmitted, the rapid progression of the new coronavirus has shown why it’s critical for blood suppliers to think ahead – and take a proactive approach to blood safety. LISTEN TO THE PODCAST Global Headquarters 1220 Concord Avenue Concord, CA US 94520 +1 925.288.6000 European Headquarters Stationsstraat 79-D 3811 MH Amersfoort, Netherlands +31 (0) 33 49 60 600 Cookie Policy and Tracking Opt-out Guide Legal Privacy Policy Copyright (c) 2020 Cerus Corporation. INTERCEPT, INTERCEPT Blood System and Cerus are trademarks of Cerus Corporation. MKT-EN 00473 v.1.0 About Cerus About Cerus Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE Mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. Follow us on LinkedIn. By continuing to use this website, you agree to the use of cookies described in our Cookies Policy. OK